Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cooperative Free Energy: Induced Protein-Protein Interactions and Cooperative Solvation in Ternary Complexes. | J Chem Theory Comput | 2025 | 40832906 | PubTator, text mining | PubMed |
| Property-Based Optimization of Cereblon-Based Molecular Glue Degraders. | ACS Med Chem Lett | 2025 | 40832542 | PubTator, text mining | PubMed |
| Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma. | Biomark Res | 2025 | 40817326 | PubTator, text mining | PubMed |
| FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia. | Sci Adv | 2025 | 40815637 | PubTator, text mining | PubMed |
| Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC. | Commun Chem | 2025 | 40813917 | PubTator, text mining | PubMed |
| Optimization and Evaluation of Complementary Degrader Discovery Assays for Application in Screening. | ACS Pharmacol Transl Sci | 2025 | 40810141 | PubTator, text mining | PubMed |
| Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies. | Front Cell Dev Biol | 2025 | 40809696 | PubTator, text mining | PubMed |
| GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism. | Blood Neoplasia | 2025 | 40792016 | PubTator, text mining | PubMed |
| A method for the detection and enrichment of endogenous cereblon substrates. | Cell Chem Biol | 2025 | 40782806 | PubTator, text mining | PubMed |
| Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro. | J Med Virol | 2025 | 40767544 | PubTator, text mining | PubMed |
| Discovery of Potent Dual PROTAC Degraders Targeting BET-Kinase To Overcome FLT3 Inhibitor Resistance. | J Med Chem | 2025 | 40764262 | PubTator, text mining | PubMed |
| Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities. | Biochem Biophys Res Commun | 2025 | 40753727 | PubTator, text mining | PubMed |
| New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy. | J Pharm Anal | 2025 | 40747342 | PubTator, text mining | PubMed |
| Graph theoretic and machine learning approaches in molecular property prediction of bladder cancer therapeutics. | Sci Rep | 2025 | 40745380 | PubTator, text mining | PubMed |
| Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs. | Commun Chem | 2025 | 40730655 | PubTator, text mining | PubMed |
| Unveiling the hidden interactome of CRBN molecular glues. | Nat Commun | 2025 | 40707481 | PubTator, text mining | PubMed |
| Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein. | J Med Chem | 2025 | 40704815 | PubTator, text mining | PubMed |
| LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia. | bioRxiv | 2025 | 40672235 | PubTator, text mining | PubMed |
| Development of PROTACs for targeted degradation of oncogenic TRK fusions. | bioRxiv | 2025 | 40666929 | PubTator, text mining | PubMed |
| Novel Highly Potent c-Met Degraders against a Broad Range of Cancers. | J Med Chem | 2025 | 40665847 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=12